The BU Annual Fund Leadership Giving Society presents a conversation with Dr.
Cambridge Firm’s Ebola Drug Carries Hope, Risk
Original article from: Boston Globe posted on August 6, 2014. By Tracy Jan & Felice J. Freyer
A Cambridge-based biotech company that has developed an experimental treatment for the Ebola virus is urging federal officials to consider allowing the unproven medication to be used on patients who have been infected in Africa’s deadly outbreak and brought to the United States for treatment.
Sarepta Therapeutics says it has enough doses of its injectible drug — AVI-7537 — to treat about two dozen patients within a week and could ramp up a supply for another 100 patients within a few months.
Such a move would be highly risky, but in the case of such a dangerous disease, the risks could be worth it in the eyes of some patients and their doctors. A different experimental drug, made by a San Diego company, has been given to two infected American relief workers who were flown to Atlanta for treatment.